BridgeBio: Product Launch
BridgeBio submitted NDA to FDA for BBP-418 for LGMD2I/R9 treatment, based on positive Phase 3 FORTIFY trial results showing statistically significant improvements
Source: GlobeNewswire
The leadership read
Product momentum tends to widen biotech & pharma product and commercial leadership bench strength.
Market context: Backdrop: a 98.6 (Neutral) Talent Market Index (down 1.4 on the month) with Americas activity easing (-2.6pts).
BridgeBio: 1 signal in the last 90 days — in line with the Biotech & Pharma median of 1 across 19 tracked companies; 0.1% of MitchelLake's Americas signal flow.
MitchelLake in this thematic
More signals across Biotech & Pharma
Product Launch · Americas
Boehringer Ingelheim →Phase 3 trial data for obesity drug survodutide shows 19% discontinuation rate due to side effects, indicating potential safety/tolerability issues that may impact market launch strategy
Product Launch · Americas
Merck & Co., Inc. →Merck presenting oncology strategy with focus on clinical progress and pipeline diversification, indicating new program developments and potential launches
Product Launch · Americas
Thermo Fisher Scientific →Thermo Fisher launched new AI-enabled Orbitrap Tribrid Apex and Orbitrap Excedion mass spectrometers at ASMS Conference, integrating with Olink proteomics and recent AI-focused software acquisitions to strengthen competitive positioning in life sciences tools.
Ma Activity · Americas
Biogen →Biogen agreed to acquire RayThera Inc., adding multiple immunology assets including a lead asset entering Phase 1 clinical development.
Partnership · Americas
Ratio Therapeutics →Ratio Therapeutics expanded manufacturing collaboration with PharmaLogic to add capacity and redundancy for clinical development of lead radiotherapeutic candidate BOSTON
Ma Activity · Americas
Gilead Sciences →Gilead Sciences acquires Tubulis GmbH for $3.15B to expand oncology portfolio
Intelligence powered by Autonodal ↗